Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded ...

A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

White & Case secures $405M jury win for Regeneron in antitrust case, with Amgen found liable for anti-competitive bundling ...

The jury after just over half a day of deliberations found Amgen Inc. liable on 10 of the 11 claims in the complaint, including monopolization and unreasonable restraint of trade in violation of the ...

US Food and Drug Administration (FDA) in a calendar year, with this year set to break this record again, analysis suggests.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...